Cargando…
Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-target...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Society of Smooth Muscle Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364263/ https://www.ncbi.nlm.nih.gov/pubmed/35944979 http://dx.doi.org/10.1540/jsmr.58.50 |
_version_ | 1784765112441110528 |
---|---|
author | Hiraishi, Keizo Kurahara, Lin Hai Ishikawa, Kaori Go, Tetsuhiko Yokota, Naoya Hu, Yaopeng Fujita, Takayuki Inoue, Ryuji Hirano, Katsuya |
author_facet | Hiraishi, Keizo Kurahara, Lin Hai Ishikawa, Kaori Go, Tetsuhiko Yokota, Naoya Hu, Yaopeng Fujita, Takayuki Inoue, Ryuji Hirano, Katsuya |
author_sort | Hiraishi, Keizo |
collection | PubMed |
description | Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-targeted therapeutics centered on pulmonary artery relaxants. It is necessary to identify the target molecules that contribute to pulmonary artery remodeling. Transient receptor potential (TRP) channels have been suggested to modulate pulmonary artery remodeling. Our study focused on the transient receptor potential ion channel subfamily M, member 7, or the TRPM7 channel, which modulates endothelial-to-mesenchymal transition and smooth muscle proliferation in the pulmonary artery. In this review, we summarize the role and expression profile of TRPM7 channels in PAH progression and discuss TRPM7 channels as possible therapeutic targets. In addition, we discuss the therapeutic effect of a Chinese herbal medicine, Ophiocordyceps sinensis (OCS), on PAH progression, which partly involves TRPM7 inhibition. |
format | Online Article Text |
id | pubmed-9364263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japan Society of Smooth Muscle Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93642632022-08-29 Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension Hiraishi, Keizo Kurahara, Lin Hai Ishikawa, Kaori Go, Tetsuhiko Yokota, Naoya Hu, Yaopeng Fujita, Takayuki Inoue, Ryuji Hirano, Katsuya J Smooth Muscle Res Invited Review Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-targeted therapeutics centered on pulmonary artery relaxants. It is necessary to identify the target molecules that contribute to pulmonary artery remodeling. Transient receptor potential (TRP) channels have been suggested to modulate pulmonary artery remodeling. Our study focused on the transient receptor potential ion channel subfamily M, member 7, or the TRPM7 channel, which modulates endothelial-to-mesenchymal transition and smooth muscle proliferation in the pulmonary artery. In this review, we summarize the role and expression profile of TRPM7 channels in PAH progression and discuss TRPM7 channels as possible therapeutic targets. In addition, we discuss the therapeutic effect of a Chinese herbal medicine, Ophiocordyceps sinensis (OCS), on PAH progression, which partly involves TRPM7 inhibition. Japan Society of Smooth Muscle Research 2022-08-10 2022 /pmc/articles/PMC9364263/ /pubmed/35944979 http://dx.doi.org/10.1540/jsmr.58.50 Text en ©2022 The Japan Society of Smooth Muscle Research https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Invited Review Hiraishi, Keizo Kurahara, Lin Hai Ishikawa, Kaori Go, Tetsuhiko Yokota, Naoya Hu, Yaopeng Fujita, Takayuki Inoue, Ryuji Hirano, Katsuya Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension |
title | Potential of the TRPM7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
title_full | Potential of the TRPM7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
title_fullStr | Potential of the TRPM7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
title_full_unstemmed | Potential of the TRPM7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
title_short | Potential of the TRPM7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
title_sort | potential of the trpm7 channel as a novel therapeutic target for pulmonary
arterial hypertension |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364263/ https://www.ncbi.nlm.nih.gov/pubmed/35944979 http://dx.doi.org/10.1540/jsmr.58.50 |
work_keys_str_mv | AT hiraishikeizo potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT kuraharalinhai potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT ishikawakaori potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT gotetsuhiko potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT yokotanaoya potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT huyaopeng potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT fujitatakayuki potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT inoueryuji potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension AT hiranokatsuya potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension |